CNS pipelines merged as Biotie buys Newron
This article was originally published in Scrip
Executive Summary
The Finnish biotech firm Biotie Therapies is to acquire the Italian company Newron Pharmaceuticals in an all-share deal valuing the latter at €45 million and the combined group at around €195 million. The merger brings together two CNS pipelines with each company contributing a late-stage product with an existing pharma partner.